Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery
There is a growing need for treatments for patients who would benefit from further weight loss following bariatric surgery or weight loss maintenance/long-term disease remission. Currently, therapeutic options are limited. Although largely dismissed previously, advances in weight loss pharmacotherapy now offer the possibility of achieving clinically significant weight loss. Historical comparisons drawn between the effects of medications vs surgery are generally inaccurate as novel classes of anti-obesity pharmacotherapy have since been developed and moreover, reflect an outdated approach in comparing medicine with surgery. Herein, we provide an overview of the most recently developed anti-obesity medications which may not only present a potentially innovative approach to medical treatment of obesity but may also inspire renewed enthusiasm for investigating what can be achieved through multimodal care.
KeywordsObesity Type 2 diabetes Bariatric surgery Anti-obesity drugs Weight loss drugs Weight regain
Compliance with Ethical Standards
This article does not contain any studies with human participants or animals performed by any of the authors. For this type of study, informed consent is not required and does not apply to our work.
Conflict of Interest
ACS has no conflict of interest to declare. CWlR reports grants from Science Foundation Ireland, grants from Health Research Board, grants from AnaBio during the conduct of the study; other from NovoNordisk, other from GI Dynamics, personal fees from Eli Lilly, grants and personal fees from Johnson and Johnson, personal fees from Sanofi Aventis, personal fees from Astra Zeneca, personal fees from Janssen, personal fees from Bristol-Myers Squibb, personal fees from Boehringer-Ingelheim, outside the submitted work and shares in Keyron. DJP reports receiving honoraria from NovoNordisk and Johnson and Johnson for lectures.
- 5.Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycaemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(2):1239–46.PubMedCrossRefPubMedCentralGoogle Scholar
- 6.Navarro M, De Fonseca R, Alvarez E, et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neruochem. 1996;67(5):1982–91.CrossRefGoogle Scholar
- 12.Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60.PubMedCrossRefPubMedCentralGoogle Scholar
- 14.O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose ranging, phase 2 trial. Lancet. 2018;392(10148):637–49.PubMedCrossRefPubMedCentralGoogle Scholar
- 16.Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.PubMedCrossRefPubMedCentralGoogle Scholar
- 17.Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomised, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.PubMedCrossRefPubMedCentralGoogle Scholar
- 18.Gustafson A, King C, Rey JA. Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity. PT. 2013;38(9):525–34.Google Scholar
- 29.Goudswaard AN, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004;18(4):CD003418.Google Scholar
- 31.Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8:CD003641.Google Scholar
- 36.Ard JD, Beavers DP, Hale E, et al. Use of phentermine/topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50kg/m2 or more. Surg Obes Relat Dis. 2019; Article in press available from https://www.soard.org/article/S1550-7289(19)30159-5/abstract. Accessed 4/6/19
- 52.Creange C, Lin E, Ren-Fielding C, et al. Use of liraglutide for weight loss in patients with prior bariatric surgery. Surg Obes Relat Dis. 2016;12(7):S157.Google Scholar
- 59.Baker C. Obesity statistics. House of Commons Library Briefing Paper No 3336; 2018. https://researchbriefings.parliament.uk/ResearchBriefing/Summary/SN03336. Accessed 4/6/19